ORAMED PHARMACEUTICALS INC. Cash Flow Statement
ORMP|10 years of annual SEC 10-K data (FY2016-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
ORAMED PHARMACEUTICALS INC. used $8M in operating cash flow and negative free cash flow of $8M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$19.1M | $5.1M | -$36.6M | -$23.0M | -$11.5M | -$14.4M | -$10.5M | -$11.0M | -$7.2M | -$5.7M |
| Depreciation & Amortization | $193.0K | $196.0K | $58.0K | $77.0K | $7.0K | $8.0K | $5.0K | $4.0K | $4.0K | $6.0K |
| Operating Cash Flow | -$8.4M | -$10.3M | -$27.9M | -$21.2M | -$12.4M | -$12.9M | -$5.8M | $4.7M | -$4.9M | -$4.1M |
| Capital Expenditures | $18.0K | $254.0K | $496.0K | $375.0K | $82.0K | $15.0K | $7.0K | $9.0K | $1.0K | $14.0K |
| Free Cash Flow | -$8.4M | -$10.5M | -$28.4M | -$21.6M | -$12.5M | -$13.0M | -$5.8M | $4.6M | -$4.9M | -$4.1M |
| Share Buybacks | $2.5M | $2.5M | - | - | - | - | - | - | - | - |
| FCF Margin | -421.5% | -787.2% | -1051.2% | -797.5% | -462.1% | -479.3% | -237.7% | 724.8% | -771.8% | -636.8% |